Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research report released on Wednesday morning. The brokerage issued a sell rating on the stock.

Oragenics Stock Down 2.5 %

OGEN opened at $0.28 on Wednesday. Oragenics has a 12-month low of $0.25 and a 12-month high of $3.43. The stock has a market cap of $3.42 million, a price-to-earnings ratio of -0.04 and a beta of 0.85. The business has a 50 day moving average of $0.30 and a 200-day moving average of $0.38.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.